Atritech is a private company located in Minneapolis, Minnesota. The company was founded in 2000 and has developed proprietary technology focused on replacing long term anticoagulation therapy for patients with non-valvular atrial fibrillation at risk of stroke. The first implants of the WATCHMANÂ® Left Atrial Appendage Closure Technology were performed in Germany in August of 2002 and in the United States in October of 2003. Since then the company has conducted a large randomized clinical trial comparing the WATCHMANÂ® Left Atrial Appendage Closure Technology to long term Warfarin therapy in patients with non-valvular atrial fibrillation at risk of stroke. The WATCHMANÂ® Device is CE Marked and available in many markets outside the United States. The WATCHMANÂ® Device is currently available For Investigational Use Only in the United States.
Boston Scientific To Acquire Device Maker Atritech For Up To $375M (fis.dowjones.com)